Cordio Validates HearO Voice Tool for Heart Failure

A pivotal trial found the voice-based monitor predicted most heart failure events weeks before they occurred.

Updated on Nov. 9, 2026 in Heart Disease

Cordio Validates HearO Voice Tool for Heart Failure

Live Poll

Would you trust an AI voice app to monitor your heart health at home?

Cordio Medical reported that its HearO voice-based tool predicted over 70% of heart failure events by an average of 24.6 days in the blinded DETECT-HF study of 563 patients. The results were presented at a late-breaking session at the 2026 American Heart Association Scientific Sessions.

Why it matters

Heart failure affects around 7.7 million patients in the United States, and conventional monitoring such as daily weight checks can be unreliable and dependent on patient adherence. An early, low-burden warning signal could give care teams time to intervene before a patient is hospitalized.

The DETECT-HF blinded study enrolled 563 patients, and HearO predicted over 70% of heart failure events by an average of 24.6 days beforehand. The extraction does not provide a comparator figure for conventional monitoring, and FDA clearance is still pending.

The players

Cordio Medical

An Israel-headquartered medical technology company that develops the HearO voice-based heart failure monitoring tool.

American Heart Association

A major US nonprofit organization focused on cardiovascular health research, which hosted the 2026 Scientific Sessions where the results were presented.

U.S. Food and Drug Administration

The federal agency that grants breakthrough device designations and will review Cordio's submission for HearO clearance.

The details

HearO builds a patient-specific voice model from short daily smartphone recordings, using speech signal processing and AI to detect changes associated with fluid accumulation in the lungs. The app-based tool notifies care teams of notable changes through a web-based portal.

Timeline

  1. 2021: HearO received FDA breakthrough device designation.

  2. 2022: HearO received a European CE mark and Israeli Ministry of Health approval.

  3. March 2026: Noah Labs' Vox secured FDA breakthrough designation.

  4. 6-9 November 2026: AHA Scientific Sessions held in Chicago, where results were presented.

  5. 2027: A full US market launch of HearO is anticipated.

Roadmap

HearO's 2021 FDA breakthrough device designation under the agency's Breakthrough Devices Program placed it on an accelerated review track, and this pivotal validation moves it toward the clearance submission that precedes a planned 2027 US launch. Noah Labs' Vox receiving a similar designation in March 2026 suggests that voice-based cardiac monitoring is becoming a recognized category within that program.

For patients already managing heart failure, a daily smartphone voice recording could eventually replace or supplement routine weight checks as a monitoring step. Once cleared, the tool would route alerts to a care team, so patients would not need to act on the signal themselves.

The takeaway

Early warning signs of heart failure may be detectable in a patient's voice before weight or symptoms change, and tools that capture these signals through everyday devices could make monitoring less burdensome. Patients should continue following their clinician's current monitoring plan until any new tool is cleared and prescribed.

What happens next

Cordio Medical plans to submit HearO to the FDA for clearance, with a full US market launch anticipated in 2027.

Further reading

For broader context on monitoring approaches, see Heart Disease coverage on Wisevoter.

Source note: This article includes information reported by Medical Device Network.

Live Poll

Would you trust an AI voice app to monitor your heart health at home?